Investors Urged to Monitor XOMA Royalty Corp Amid Securities Fraud Investigation by Pomerantz Law Firm

Introduction

XOMA Royalty Corporation, a prominent player in the biopharmaceutical sector, has come under scrutiny as Pomerantz LLP begins investigating possible claims of securities fraud. This probe arises amidst unsettling news regarding XOMA's developmental partner, Rezolute Inc., which recently disclosed significant setbacks in a key clinical study. Investors are urged to stay vigilant and informed about the developments impacting their investments in XOMA.

Background on XOMA

Founded with a commitment to delivering innovative solutions for complex medical conditions, XOMA Royalty Corporation operates on the NASDAQ under the ticker symbol XOMA. Their portfolio includes a variety of therapeutic assets, with a focus on high-value biotech projects. By partnering with other firms such as Rezolute, XOMA aims to bring forth groundbreaking therapies to market.

The Investigation

Pomerantz LLP, a leading law firm known for its prowess in corporate securities litigation, is reaching out to investors of XOMA to inquire about their experiences and any potential claims. The firm is particularly deconstructing whether XOMA and its executives engaged in misleading business practices or violated securities laws. This investigation is set against the backdrop of substantial fluctuations in XOMA’s stock value, following disappointing results from Rezolute’s recent clinical trial, which aimed to evaluate a novel treatment for congenital hyperinsulinism (HI).

Recent Developments with Rezolute

On December 11, 2025, Rezolute publicly shared the findings from its much-anticipated Phase 3 clinical trial, aptly named the sunRIZE study. The company announced that the study failed to meet its primary endpoint concerning the reduction of hypoglycemia events in patients receiving ersodetug, the investigational treatment. The reported 45% reduction in hypoglycemic events with the top dose of 10 mg/kg was found to lack statistical significance when compared to the placebo group, which demonstrated a 40% improvement. Furthermore, critical secondary endpoints regarding the daily duration of hypoglycemia also fell short of expectations, sparking disappointment in both clinical and investor circles.

The resulting fallout was severe. After these disclosures, XOMA’s stock price plummeted by nearly 23%, closing at $25.39 per share, a sharp decline indicative of investor concern and loss of confidence in the company’s future.

Implications for Investors

Given these rapid developments, Pomerantz LLP is proactively encouraging XOMA's investors to contact them if they believe they have suffered losses due to these disclosures and the potential securities fraud. As experts in class-action litigation, they provide a platform for affected investors to join forces against alleged corporate misconduct. This proactive approach aims to recover losses through legal means, reinforcing the rights of investors in an increasingly volatile market.

Pomerantz LLP’s Commitment

Pomerantz LLP has a storied legacy in advocating for the rights of investors who have been victims of corporate misconduct. With over 85 years in operation, they have established a formidable track record of securing compensation for clients affected by securities fraud. Their strategic focus on corporate accountability and justice aligns with their mission to safeguard investor rights.

Conclusion

As Pomerantz LLP dives deeper into its investigation, the implications for both XOMA and its investors remain significant. Investors are advised to stay alert to any new developments and consider reaching out to Pomerantz LLP to discuss their options. In a time when the integrity of corporate behavior is constantly being tested, staying informed and proactive is paramount for every investor.

Call to Action

Investors interested in discussing potential claims regarding XOMA Royalty Corporation should contact Danielle Peyton at Pomerantz LLP via [email protected] or call 646-581-9980, ext. 7980. Stay informed and protect your investments as this situation unfolds.